Personalis
Personalis, Inc. offers global genomic sequencing and analytics, aiding in the development of personalized cancer treatments.
Founded
2011Personalis, Inc. offers global genomic sequencing and analytics, aiding in the development of personalized cancer treatments.
Founded in Menlo Park, United States, Personalis, Inc. is dedicated to advancing the field of precision oncology through genomic sequencing and analytics solutions. The company's core mission is to support the development of personalized cancer vaccines and next-generation cancer immunotherapies. Personalis offers comprehensive end-to-end solutions for immuno-oncology and precision oncology applications, aiming to transform the future of cancer care by providing advanced insights and earlier detection methods.
Personalis has garnered attention from notable investors and industry leaders due to its innovative approach to cancer treatment. The company has achieved significant milestones, including the development of advanced whole-exome based approaches and personalized therapy selection tools. By delivering cutting-edge genomic insights as cancer evolves, Personalis has made a substantial impact on the global healthcare market, aiding in the creation of more effective and personalized cancer treatments.
Companies similar to Personalis include Personal Genome Diagnostics, AccuraGen, Foundation Medicine and BostonGene.
Personalis was founded in 2011.
Personalis' headquarters is located in Menlo Park, CA, US.
Personalis' most recent funding round was for $150.1M (USD) in January 2021.
As of Jan 27, 2021, Personalis has disclosed funding of $225.1M (USD). Undisclosed round amounts are excluded.
Personalis has 399 employees as of Feb 6, 2024.
BostonGene
bostongene.com
